Our modular plug-and-play shuttle restores therapeutic concentrations in the CNS for antibodies, enzymes, and oligonucleotides.
Founded in 2021 and headquartered in Cambridge, UK, Dianoya is solving the fundamental challenge of neuro-drug development: the Blood-Brain Barrier. By hijacking the body's natural iron transport mechanism, we turn large molecule therapeutics into brain-penetrant precision medicines.
| Programme | Modality | Target / Indication | Status | Rights |
|---|---|---|---|---|
|
DI-001
|
TfR-Antibody Fusion
|
BACE1 / Alzheimer's
|
IND Enabling |
Wholly Owned
|
|
DI-101 (ASO)
|
TfR-Oligonucleotide
|
MAPT / Tauopathy
|
Discovery |
Wholly Owned
|
|
Undisclosed
|
TfR-Antibody
|
Neuro-Oncology
|
Discovery |
Active Discussions (3)
|
Previous BACE inhibitors (Merck, Lilly, Janssen) failed due to peripheral target engagement causing cognitive decline. Our brain-selective delivery achieves 40:1 brain:plasma exposure, enabling CNS-specific Aβ reduction without systemic BACE1 inhibition. Pre-IND meeting scheduled Q1 2026.
Unlike high-affinity TfR binders that trigger lysosomal degradation, our bivalent shuttle uses moderate affinity (Kd ~0.3nM) with pH-dependent release kinetics, validated across three NHP studies showing consistent parenchymal distribution and no reticulocyte depletion at therapeutic doses.
We focus wholly-owned development on high-value CNS targets where brain delivery is the primary failure mode. Platform partnerships are opportunistic and limited to indications outside our core focus (e.g., neuro-oncology).
DI-001 demonstrates broad parenchymal distribution with a favorable brain:plasma ratio of 38:1, confirming active transport rather than vascular pooling.
Qualified institutional investors may request access to our virtual data room containing full preclinical data packages, CMC overview, and IP landscape.